Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

System and process for neuroprotective therapy for glaucoma

A neuroprotective, glaucoma technology, applied in the field of neuroprotective therapy for glaucoma, can solve problems such as reducing clear clinical efficacy

Active Publication Date: 2018-12-21
OJAI RETINAL TECH
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While many therapies hold promise for neuroprotection, none to date have demonstrated definitive clinical efficacy beyond IOP reduction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • System and process for neuroprotective therapy for glaucoma
  • System and process for neuroprotective therapy for glaucoma
  • System and process for neuroprotective therapy for glaucoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0052] The present invention relates to a system and method for treating glaucoma. More specifically, the present invention relates to a system and method for providing neuroprotective therapy for glaucoma using predetermined parameters to generate harmless yet therapeutic true subthreshold photocoagulation.

[0053] The inventors have found that retinal laser treatment does not cause any laser-induced retinal damage, but is at least as effective as conventional retinal photocoagulation, contrary to conventional wisdom and practice. Conventional thinking assumes that physicians must deliberately produce retinal damage as a prerequisite for therapeutically effective management.

[0054]Referring to Figure 2, Figures 2A-2D are graphical representations of the effective surface area of ​​various modes of retinal laser treatment for retinal vascular disease. The gray background represents the retina 18 unaffected by the laser treatment. The black area 24 is the area of ​​the ret...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Wavelengthaaaaaaaaaa
Pulse lengthaaaaaaaaaa
Login to View More

Abstract

Provided is neuroprotective therapy for glaucoma which includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selectedto create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and / or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and / or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and / or foveal tissue and improve function or condition of an optic nerve and / or retinal ganglion cells of the eye.

Description

technical field [0001] The present invention generally relates to the treatment of glaucoma. More specifically, the present invention relates to systems and methods for providing harmless subthreshold phototherapy or photostimulation of the retina, which improves the function or condition of the optic nerve of the eye, and provides neuroprotective therapy for glaucoma. Background technique [0002] Complications of diabetic retinopathy remain the leading cause of vision loss in people under the age of sixty. Diabetic macular edema is the most common cause of legal blindness in this patient population. Diabetic retinopathy and thus diabetic macular edema, the cause of diabetes, is increasing in global incidence and prevalence, becoming endemic not only in the developed world, but also in developing countries. Diabetic retinopathy may begin to develop in patients with type 1 (insulin-dependent) diabetes within three to five years of onset. The prevalence of diabetic retinop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61F9/008
CPCA61F9/008A61F2009/00863A61F2009/00891
Inventor J·K·卢特鲁勒B·W·L·马戈利斯D·B·昌
Owner OJAI RETINAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com